News

VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.

Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...

VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.

Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.

Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.9% to $514.18 per share while the index has gained 14%.

This company has had plenty of setbacks in recent years, but it generally bounces back.

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.

Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.

In August 2026, Vertex Pharmaceuticals announced that Senior Vice President of Finance Jonathan Poole will become Executive Vice President and Chief Financial Officer on January 1, 2027, while Charles F. Wagner Jr. remains Executive Vice President and Chief Operating Officer. This internal promotion, paired with Vertex’s increased external visibility through forums such as the Boston C-Level Technology Leadership Summit, highlights how the company is elevating both its financial leadership...

Vertex Pharmaceuticals (VRTX) has been in focus after presenting at the 18th Annual Boston C-Level Technology Leadership Summit on September 10, where its Chief Digital and Information Officer outlined the group’s technology priorities. Recent trading has been choppy for Vertex Pharmaceuticals, with the share price falling 4.9% over the past week but still showing a 14.6% 90 day share price return and a 32.1% 1 year total shareholder return. This points to momentum that has built over a...

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.

Vera stock jumped Tuesday on positive test results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex Pharmaceuticals.

CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026. Kulkarni said the company’s stra

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s priorities, CEO and President Reshma Kewalramani said at Morgan Stanley’s 24th Annual Healthcare Conferen

Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.

Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance. Susie Lisa, the company’s head of investor relations, s

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis an

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […]

Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.